Core Points - The document outlines the fundraising management system of Beijing Kejingyuan Technology Co., Ltd, aiming to regulate the management of raised funds, improve usage efficiency, and protect shareholders' interests [1][2] Group 1: Fundraising Management Principles - The company must ensure the feasibility of investment projects and prevent risks while enhancing the effectiveness of fund usage [3][4] - The board of directors and senior management are responsible for the proper use of raised funds and must not change their intended use without proper authorization [4][5] - A specialized account must be established for the storage and management of raised funds, which should not be mixed with other funds [8][9] Group 2: Fund Usage Regulations - Raised funds should primarily be used for the company's main business and not for high-risk investments or financial investments [5][6] - Any changes to the intended use of funds must be approved by the shareholders' meeting [10][11] - The company must disclose the actual usage of raised funds accurately and promptly, especially if there are significant deviations from the planned investment [12][13] Group 3: Supervision and Reporting - The company is required to conduct semi-annual reviews of the fundraising projects and report on the status of fund usage [26][27] - Independent directors must monitor the actual management and usage of funds, and they can hire external auditors for verification [28][29] - Any discrepancies in fund usage must be reported and justified in the company's annual reports [14][15]

Fundraising Overview - The company raised a total of RMB 3,255,615,848.10 from its initial public offering, with a net amount of RMB 3,067,814,636.72 after deducting issuance costs [1][2] - As of June 30, 2025, the balance of the raised funds was RMB 1,326,809,869.83, after using RMB 162,305,087.78 during the reporting period [1][2] Fund Management - The company has established a fundraising management system in accordance with relevant regulations, ensuring proper storage, usage, and supervision of the raised funds [1][2] - A tripartite or quadripartite supervision agreement has been signed with banks and sponsors to ensure strict approval for the use of funds, maintaining dedicated usage [1][2] Fund Usage - The company temporarily supplemented working capital with RMB 40,000,000.00 of idle raised funds, which will be used for business expansion and R&D project expenses [2][3] - The company has not engaged in any early investment or replacement of fundraising projects during the reporting period [2][3] Cash Management - The company has been authorized to manage idle funds by investing in safe, liquid, principal-protected products, with a maximum of RMB 170,000,000.00 allocated for this purpose [2][3] - As of June 30, 2025, the company had a total of RMB 1,320,000,000.00 in cash management products [3][4] Project Investment Status - The company has not used any over-raised funds for permanent working capital supplementation or loan repayment during the reporting period [4][5] - There have been no changes in the use of fundraising projects or delays in project timelines reported [4][5]

Core Points - The company emphasizes the importance of accurately disclosing the actual use of raised funds and ensuring their safety and effectiveness [1][4][6] - The management of raised funds must comply with national industrial policies and relevant laws, primarily focusing on enhancing the company's competitiveness and innovation capabilities [2][6] - Any changes in the use of raised funds require approval from the shareholders' meeting and must adhere to information disclosure obligations [2][8] Fund Management and Use - The company must establish a dedicated account for raised funds, ensuring that these funds are not mixed with other funds or used for unauthorized purposes [9][10] - A tripartite supervision agreement must be signed with the sponsor institution and the commercial bank to oversee the use of raised funds [10][11] - The company is required to conduct a comprehensive review of the progress of investment projects every six months and disclose the findings in a special report [5][14] Fund Usage Restrictions - Raised funds should primarily be used for the main business and cannot be used for high-risk investments or financial investments [6][12] - If the actual investment progress deviates significantly from the planned investment, the company must explain the reasons and adjust the investment plan accordingly [14][31] - The company must ensure that raised funds are not misappropriated by controlling shareholders or related parties [6][12] Changes in Fund Use - Any change in the use of raised funds must be approved by the board of directors and the shareholders' meeting, with clear justifications provided [20][24] - The company must conduct feasibility analyses for new investment projects to ensure they have good market prospects and profitability [20][28] - The company must disclose any changes in the implementation location of investment projects and the reasons for such changes [20][29]

Core Viewpoint - The document outlines the regulations and procedures for the management and use of raised funds by Shenzhen Zhengzhong Design Co., Ltd, ensuring investor protection and compliance with relevant laws and regulations [1][2][3]. Group 1: Fund Management and Storage - The company must use raised funds prudently and ensure that their use aligns with the commitments made in the issuance application documents [2][3]. - A special account for raised funds must be established and managed, ensuring that no non-raised funds are stored in this account [2][3]. - A tripartite supervision agreement must be signed with the sponsor or independent financial advisor and the commercial bank within one month of the funds being in place [2][3][4]. Group 2: Fund Usage - Raised funds should primarily be used for the company's main business and not for high-risk investments or financial assistance to others [3][4]. - The company must ensure the authenticity and fairness of fund usage, preventing misuse by controlling shareholders or related parties [3][4]. - If any project funded by raised funds encounters significant issues, the company must reassess its feasibility and disclose the situation [3][4][5]. Group 3: Changes in Fund Usage - Any changes in the use of raised funds must be approved by the board of directors and disclosed promptly [4][5][10]. - The company must have a clear plan for the use of any excess funds raised, which should be allocated to ongoing projects or share buybacks [10][12]. - If the company intends to change the implementation subject of the raised funds, it must ensure effective control over the project [12][13]. Group 4: Supervision and Reporting - The company’s audit department must conduct quarterly checks on the storage, management, and usage of raised funds [14][15]. - The board of directors must monitor the actual storage and usage of raised funds and report any discrepancies exceeding 30% from the planned investment [14][15]. - Independent financial advisors must conduct regular on-site checks and report any irregularities in the management of raised funds [15][16].

Core Points - The document outlines the fundraising management system of Weijie Chuangxin (Tianjin) Electronics Technology Co., Ltd, aiming to regulate the management and usage of raised funds to enhance efficiency [1][2] - The company must ensure the safety of raised funds and cannot change their intended use without proper procedures [3][4] - The management and usage of raised funds must comply with relevant laws and regulations, including the Securities Law and the Shanghai Stock Exchange rules [1][5] Fundraising Management - The company must establish a special account for managing raised funds, which should not be used for non-fundraising purposes [7][8] - A tripartite supervision agreement must be signed with the sponsor institution and the commercial bank where the funds are stored [11][12] - The company is required to conduct a verification of the raised funds by a qualified accounting firm upon receipt [10] Fund Usage - Funds must be used according to the planned investment projects as stated in the issuance application documents [12][13] - Any significant changes affecting the normal execution of the investment plan must be promptly disclosed [12][14] - The company is prohibited from using raised funds for financial investments or providing funds to related parties for improper benefits [14][15] Cash Management - Temporarily idle raised funds can be managed through safe financial products, ensuring they do not affect the normal investment plan [17][18] - Any temporary use of raised funds for working capital must be approved by the board and disclosed [20][21] Oversight and Reporting - The company must regularly disclose the actual usage of raised funds and any discrepancies in investment progress [34][35] - The sponsor institution is responsible for ongoing supervision and must report any irregularities to regulatory authorities [36][37] Changes in Fund Usage - Any changes in the intended use of raised funds require board approval and must be disclosed to shareholders [29][30] - The company must conduct feasibility analyses for new projects and ensure they align with the main business [31][32]

除上述结息收入以外，"硕世生物泰州总部产业园项目中的医学检验场所" | 募集资金已投入完毕，无节余。 | 鉴于"硕世生物泰州总部产业园项目中的医学检验场所"已投资完成，项目 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2022 年 | 4 月 | 已达到可使用状态，该项目募集资金账户无后续使用计划，公司于 | 2023 年 | 4 月 | 25 日召开的第二届董事会第二十一次会议及第二届监事 | 公司于 | | | | 会第十四次会议审议通过了《首次公开发行募集资金项目以及超募投资项目结项 | 的议案》，同意公司将首次公开发行募集资金项目以及超募投资项目结项。 | | | | | | | | | 鉴于公司首次公开发行募集资金投资项目"硕世生物泰州总部产业园项目" | 及超募资金投资项目"硕世生物快速检测产品项目"已建设完毕并达到可使用状 | | | | | | | | | 态，为进一步提高募集资金使用效率，公司拟将该项目结项。 | 针对节余募集资金，公司后续将根据自身发展规划及实际生产经营需要，按 | | ...

普源精电科技股份有限公司 募集资金使用管理办法 （草案） （H股发行上市后适用） 第一章 总则 第一条 为规范普源精电科技股份有限公司（以下简称"公司"）募集资金的管 理和运用，保证募集资金的安全，提高募集资金的使用效益，保护投资者的合法权 益，根据《中华人民共和国公司法》《中华人民共和国证券法》《首次公开发行股 票注册管理办法》《上市公司证券发行注册管理办法》《上市公司监管指引第2号 第三条 公司董事会负责建立健全公司募集资金使用管理制度，并确保制度的有 效实施。募集资金投资项目（以下简称"募投项目"）通过公司的子公司或公司控 制的其他企业实施的，公司的子公司或受控制的其他企业同样受本办法的约束。 第二章 募集资金专户存储 第四条 公司募集资金应当存放于董事会批准设立的专项账户（以下简称"募集 资金专户"）集中管理。募集资金专户不得存放非募集资金或用作其他用途。 第五条 公司应当在募集资金到账后1个月内与保荐机构、存放募集资金的商业 银行（以下简称"商业银行"）签订募集资金专户存储三方监管协议（以下简称"协 议"）。协议至少应当包括以下内容： （一）公司应当将募集资金集中存放于募集资金专户； ——上市公司募 ...

募集资金三方监管协议的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 青岛海泰科模塑科技股份有限公司 关于开立募集资金临时补流专项账户并签署 证券代码：301022 证券简称：海泰科 公告编号：2025-107 债券代码：123200 债券简称：海泰转债 一、募集资金基本情况 经中国证券监督管理委员会出具的《关于同意青岛海泰科模塑科技股份有限 公司向不特定对象发行可转换公司债券注册的批复》（证监许可〔2023〕1053 号） 同意注册，青岛海泰科模塑科技股份有限公司（以下简称"公司"）向不特定对象 发行可转换公司债券 3,965,716 张，每张面值为人民币 100 元，募集资金总额为人 民币 396,571,600.00 元。扣除发行费用（不含税）人民币 5,196,011.53 元后，实际 募集资金净额为人民币 391,375,588.47 元。 公司募集资金已于 2023 年 7 月 3 日到账，并经中兴华会计师事务所（特殊普 通合伙）进行了审验，出具了《验资报告》（中兴华验字（2023）第 030019 号）。 公司已按规定对募集资金进行了专户存 ...

Core Viewpoint - The company has approved a cash dividend distribution plan for the first half of 2025, proposing a distribution of 0.15 RMB per share, amounting to a total of 15 million RMB, which represents 24.01% of the net profit attributable to shareholders for the period [3][30][32]. Company Overview - The company is named Shenghui Integration Group Co., Ltd., with the stock code 603163 [4]. - The company held its third board meeting on August 7, 2025, where all directors were present, and the meeting was conducted in compliance with relevant laws and regulations [6][8]. Financial Data - As of June 30, 2025, the company's total share capital was 100 million shares, and the distributable profit was 121,188,429.66 RMB [32]. - The total amount of cash dividends to be distributed is 15 million RMB, based on the total share capital [30][32]. Profit Distribution Plan - The profit distribution plan was approved by the board of directors and does not require further approval from the shareholders' meeting [3][11][34]. - The distribution will be based on the total share capital as of the record date for the dividend [30][31]. Fundraising and Usage - The company raised a total of 545 million RMB from its initial public offering, with a net amount of 485,347,160.34 RMB after deducting issuance costs [14]. - As of June 30, 2025, the company had utilized 472,955,538.03 RMB of the raised funds, with 14 million RMB in cash management and a remaining balance of 1,735,466.43 RMB in the special account [16][18]. Significant Events - The company has not experienced any significant changes in its operational situation during the reporting period [5]. - The board approved a report on the actual use of raised funds, confirming compliance with relevant regulations [10][14].

Core Points - The company has reported its fundraising management and usage situation for the first half of 2025, ensuring compliance with relevant regulations and confirming the accuracy of the report [2][11][24] Group 1: Fundraising Overview - The company raised a total of RMB 2,545,464,000 through the issuance of 40,200,000 shares at a price of RMB 63.32 per share, with a net amount of RMB 2,441,134,463.77 after deducting issuance costs [2][3] - As of June 30, 2025, the company has utilized RMB 2,081,956,363.27 of the raised funds, with RMB 264,416,471.27 remaining in the fundraising account [3][7] Group 2: Fundraising Management - The company has established a fundraising management system in accordance with relevant laws and regulations, ensuring that funds are stored in a dedicated account and managed under a three-party supervision agreement [4][5] - The company has not used idle funds for temporary working capital during the reporting period [8] Group 3: Investment Projects - The company has approved the use of RMB 1,521,624,608.07 of the raised funds to replace self-raised funds previously invested in fundraising projects [7][11] - The insulin industrialization project has achieved significant financial results, with a cumulative profit of RMB 1,120,138.69 million and a net profit of RMB 952,117.89 million as of June 30, 2025 [12]